UNSPSC 51123700: Antiarrythmic cyclic hydrocarbons

This classification denotes organic compounds composed of carbon and hydrogen alone (hydrogen-carbon), but forming a closed ring, substances called cyclic hydrocarbons, that prevent or treat irregular heartbeat, disturbances of normal rhythmic heart beating, or normal operation of myocardial contraction, thus the term ANTIARRYTHMIC CYCLIC HYDROCARBONS.

UNSPSC 51123700 Antiarrhythmic cyclic hydrocarbons, a Class code, covers the supply of emergency and critical-care medications—specifically antiarrhythmic agents and related advanced life support drugs—to state and local health systems, fire rescue departments, and pharmacy benefit programs. State and local governments purchase these medications for emergency medical services, hospital formularies, and state health plan distribution networks. Issuing bodies include municipal fire and emergency services departments (Tampa Fire Rescue), state health authorities (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multi-state government jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance). The code also encompasses broader pharmaceutical supply agreements where antiarrhythmics are part of generic multi-source drug catalogs distributed through authorized wholesalers to state and local facilities.

Recent activity centers in Florida, Texas, and the upper Midwest. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26P00188) on April 24, 2026, for Advanced Life Support Medications including 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with responses due April 8, 2026, and an estimated contract value of $40,000 under a one-year term with two optional one-year renewals and three 30-day extensions; the solicitation included a 5 percent small local business enterprise bid discount. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued an RFP (S1070000015802) due March 26, 2026, to establish multi-award contracts for generic pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with pricing weighted at 75 percent and compliance with cGMP and the Drug Supply Chain Security Act required. Texas Health and Human Services Commission issued an RFI (HHS0017013) posted April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, signaling early-stage market exploration before formal procurement.